Related Experiment Video
Updated: Apr 20, 2026
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
Published on: June 5, 2019
Immune thrombocytopenia
Insights
Childhood immune thrombocytopenia (ITP) is typically mild, diagnosed clinically, and treated with options like IVIG or steroids. While rare, serious complications like intracranial hemorrhage can occur.
Area of Science:
- Pediatric Hematology
- Immunology
- Autoimmune Disorders
Background:
- Immune thrombocytopenia (ITP) in children is an autoimmune condition causing low platelet counts.
- It typically presents with bruising and petechiae in otherwise healthy children.
- Diagnosis relies heavily on clinical presentation, minimizing extensive lab work.
Purpose of the Study:
- To review the diagnosis and management of childhood ITP.
- To outline current treatment options and their indications.
- To discuss potential complications and future research directions.
Main Methods:
- Clinical review of immune thrombocytopenia in pediatric patients.
- Summary of diagnostic criteria and laboratory investigations.
- Overview of available therapeutic modalities and their efficacy.
Main Results:
- ITP is generally benign with clinical diagnosis being key.
- Treatment indications are variable, focusing on bleeding, anxiety, and quality of life.
- Common treatments include IVIG, steroids, and WinRho (anti-D), effectively increasing platelet counts.
Conclusions:
- Childhood ITP is usually self-limiting, with diagnosis primarily clinical.
- Treatment decisions are individualized based on symptoms and impact on quality of life.
- Further research into molecular targets may offer novel therapeutic strategies for ITP.
Abstract:
Immune thrombocytopenia (ITP) in children is a relatively uncommon and generally benign condition presenting as abrupt onset of bruising, petechiae and thrombocytopenia in an otherwise healthy child due to production of anti-platelet autoantibodies. Diagnosis is largely clinical and laboratory investigation should be kept to a minimum. Indications for treatment have not been standardized and include bleeding, parental anxiety and quality of life. Multiple treatments are available that have been proven to increase the platelet count; the most commonly employed include IVIG, steroids and WinRho (anti-D). Intracranial hemorrhage is the most serious potential complication but is extremely rare and splenectomy is reserved for chronically symptomatic patients who have not responded to other modalities. Identification of molecular targets may be a promising avenue for future research.
Related Concept Videos
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:25Endocarditis II: Clinical Features of Infective Endocarditis